Cantor Fitzgerald Boosts Earnings Estimates for CVS Health

Key Points

• Analysts at Cantor Fitzgerald raised their FY2025 earnings estimate for CVS Health to $6.38 per share, indicating confidence in the company’s financial performance.
• CVS Health declared a quarterly dividend of $0.665 per share, resulting in a 3.4% dividend yield, with the payment set for November 3rd to investors of record by October 23rd.
• Wells Fargo upgraded CVS Health's price target from $84.00 to $103.00, reflecting positive sentiment from several brokerages that rated the stock as a strong buy.

CVS Health Corporation (NYSE:CVS - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of CVS Health in a research note issued on Monday, October 13th. Cantor Fitzgerald analyst S. James now expects that the pharmacy operator will earn $6.38 per share for the year, up from their prior estimate of $6.36. Cantor Fitzgerald has a "Overweight" rating and a $78.00 price target on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Cantor Fitzgerald also issued estimates for CVS Health's FY2026 earnings at $7.09 EPS.

Several other brokerages have also weighed in on CVS. Wells Fargo & Company increased their price objective on shares of CVS Health from $84.00 to $103.00 and gave the stock an "overweight" rating in a report on Tuesday, October 7th. Weiss Ratings restated a "hold (c-)" rating on shares of CVS Health in a report on Saturday, September 27th. Baird R W upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Mizuho raised their price target on shares of CVS Health from $76.00 to $88.00 and gave the company an "outperform" rating in a report on Thursday, October 9th. Finally, Cowen restated a "buy" rating on shares of CVS Health in a report on Monday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $80.33.

CVS Health Trading Up 0.8%

Shares of CVS stock opened at $78.50 on Tuesday. The firm has a market cap of $99.56 billion, a P/E ratio of 21.93, a PEG ratio of 0.86 and a beta of 0.60. CVS Health has a 1-year low of $43.56 and a 1-year high of $79.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.80 and a quick ratio of 0.62. The firm's 50-day simple moving average is $72.63 and its 200-day simple moving average is $67.75.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The company had revenue of $98.92 billion for the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is 74.30%.

Insider Activity

In related news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.22% of the company's stock.

Hedge Funds Weigh In On CVS Health

Hedge funds have recently added to or reduced their stakes in the business. Avion Wealth boosted its holdings in CVS Health by 99.0% in the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 189 shares during the period. Harbor Asset Planning Inc. acquired a new position in shares of CVS Health during the second quarter valued at $30,000. Bell Investment Advisors Inc boosted its holdings in shares of CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after acquiring an additional 248 shares during the period. Front Row Advisors LLC lifted its holdings in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator's stock worth $31,000 after purchasing an additional 371 shares during the period. Finally, Roxbury Financial LLC lifted its holdings in CVS Health by 78.3% in the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 202 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.